Cytoreductive surgery for advanced epithelial tumors of the ovary: technical considerations and outcome.
To study the role of cytoreductive surgery in the management of advanced epithelial tumors of the ovary and its effect on survival. A prospective study of fifty eight female patients presenting with stage III and VI epithelial ovarian tumors attending the National Cancer Institute, Cairo University during the period from January 2003 to of December 2004. All patients were evaluated clinically, radiologically (including plain chest-X-ray and abdomino-pelvic ultrasound and/or CT), laboratory work up and CA-125. Abdominal exploration under general anesthesia with intent of maximum surgical cytoreduction was performed for all patients. Patients were followed up during the period of the study by history and physical examination, CA-125 measurement and abdomino-pelvic ultrasound or CT. Our study included 58 female patients with advanced epithelial tumors of the ovary. Their age ranged from 18 to 73 years with a mean age of 49 years. Pathological distribution of the lesions were borderline malignancy in 5 patients (8.6%) and malignant in 53 patients (91.4%). According to FIGO classification there were 46 patients stage III (79%) and 12 patients stage VI disease (21%). Eighteen patients (31%) had surgery prior to admission to NCI. Cytoreductive surgery was done for 51 patients (88%), while 7 patients (12%) had exploration and biopsy only, one of whom had palliative colostomy for large bowel obstruction. Intraoperative surgical complications were encountered in 5 patients (8.6%), all were managed intraoperatively. We had no early postoperative mortalities and 8 postoperative morbidities (13.7%). All patients were referred for chemotherapy. Thirteen patients (22.4%) had local recurrence within the follow up period of the study which was between 8-24 months. One patient died from locally advanced disease and the rest of the patients were explored and lesions were surgically resected. Surgery remains a major line of therapy in ovarian cancer including advanced lesions. Extensive procedures to maintain a R0 result are crucial to reach a satisfactory local disease control. The NCI, as well as all tertiary cancer centers, has an important role in providing this quality of surgery especially in advanced cases. Chemotherapy remains the hope to ameliorate the survival especially in advanced cases. The close coordination between surgery and chemotherapy in the form of Intra- Peritoneal Hyperthermic Chemotherapy (IPHC) represents a hope for patients with advanced disease and should be introduced and established in all major cancer centers.